Lemtrada (alemtuzumab) is a monoclonal antibody (mAb) authorized for the treatment of adults with relapsing-remitting multiple sclerosis (MS). Some recent significant safety findings for this MS drug safety findings include Lemtrada cardiovascular reactions and Lemtrada immune-mediated reactions. The UK Medicines and Healthcare Products … [Read more...]
Lemtrada Adverse Events: Ten Deaths Related To Lemtrada, According To New Medical Journal Article
Lemtrada adverse events (AEs) may occur more frequently than previously understood, according to an August 2019 medical journal article. This new Lemtrada drug safety information appeared in this article, “Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis”, published August 12, 2019 by BMC Research … [Read more...]
Lemtrada Drug Safety Update: Use Restrictions And Patient Monitoring For Side Effects
On May 17, 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Lemtrada Drug Safety Update, “Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements”, we get this summary: While an urgent [European Union (EU)] safety … [Read more...]